Therapeutic nanoparticles to combat cancer drug resistance

Current Drug Metabolism

Volumn 10, Issue 8, 2009, Pages 836-841

  Hu, Che Ming Jack ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer chemoresistance; Combination therapy; Endocytic uptake; Long circulation; Nanoparticle drug delivery; Stimuli responsive drug release; Targeted delivery

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CURCUMIN; CYCLOSPORIN A; DOXORUBICIN; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYCAPROLACTONE; POLYLACTIC ACID;

AREA UNDER THE CURVE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; KAPOSI SARCOMA; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CARCINOMA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; P-GLYCOPROTEINS;

EID: 74249101977     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790274540     Document Type: Review

References (58)

1. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53, 615-627.
2. Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am., 1994, 271(1), 58-65.
3. Bonadonna, G.; Zucali, R.; Monfardini, S.; De Lena, M.; Uslenghi, C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer, 1975, 36(1), 252-259.
4. Scheithauer, W.; Rosen, H.; Kornek, G. V.; Sebesta, C.; Depisch, D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ, 1993, 306(6880), 752-755.
5. Bebawy, M.; Chetty, M. Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr. Drug Metab., 2009, 10(4), 322-328.
6. Bradshaw, D. M.; Arceci, R. J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol., 1998, 16(11), 3674-3690.
7. Hennessy, M.; Spiers, J.P. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Res., 2007, 55(1), 1-15.
8. Yuan, H.; Li, X.; Wu, J.; Li, J.; Qu, X.; Xu, W.; Tang, W. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr. Med. Chem., 2008, 15(5), 470-476.
9. Couvreur, P.; Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharmacol. Res., 2006, 23(7), 1417-1450.
10. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782.
11. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83(5), 761-769.
12. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
13. Ganta, S.; Amiji, M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm., 2009, 6(3), 928-939.
14. Kobayashi, T.; Ishida, T.; Okada, Y.; Ise, S.; Harashima, H.; Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm., 2007, 329(1-2), 94-102.
15. Soma, C. E.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials, 2000, 21(1), 1-7.
16. Patel, N.H.; Rothenberg, M. L. Multidrug resistance in cancer chemotherapy. Invest. New Drugs. 1994, 12(1), 1-13.
17. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41, 189-207.
18. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46(12 Pt 1), 6387-6392.
19. Tanaka, T.; Shiramoto, S.; Miyashita, M.; Fujishima, Y.; Kaneo, Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm., 2004, 277(1-2), 39-61.
20. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4(2), 145-160.
21. Ballou, B.; Lagerholm, B. C.; Ernst, L. A.; Bruchez, M. P.; Waggoner, A. S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem., 2004, 15(1), 79-86.
22. Carpenter, C. P.; Woodside, M. D.; Kinkead, E. R.; King, J. M.; Sullivan, L. J. Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicol. Appl. Pharmacol., 1971, 18(1), 35-40.
23. Uchida, K.; Otsuka, H.; Kaneko, M.; Kataoka, K.; Nagasaki, Y. A reactive poly(ethylene glycol) layer to achieve specific surface plasmon resonance sensing with a high S/N ratio: the substantial role of a short underbrushed PEG layer in minimizing nonspecific adsorption. Anal. Chem., 2005, 77(4), 1075-1080.
24. Jiang, W.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol., 2008, 3(3), 145-150.
25. Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett., 2009, 9(5), 1909-1915.
26. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet., 2003, 42(5), 419-436.
27. Li, Y.; Pei, Y.; Zhang, X.; Gu, Z.; Zhou, Z.; Yuan, W.; Zhou, J.; Zhu, J.; Gao, X., PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release, 2001, 71(2), 203-211.
28. Peracchia, M. T.; Fattal, E.; Desmaele, D.; Besnard, M.; Noel, J. P.; Gomis, J. M.; Appel, M.; d'Angelo, J.; Couvreur, P., Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release, 1999, 60(1), 121-128.
29. Park, J. W.; Kirpotin, D. B.; Hong, K.; Shalaby, R.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Papahadjopoulos, D.; Benz, C. C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release, 2001, 74(1-3), 95-113.
30. Kamps, J. A.; Koning, G. A.; Velinova, M. J.; Morselt, H. W.; Wilkens, M.; Gorter, A.; Donga, J.; Scherphof, G. L., Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J. Drug Target, 2000, 8(4), 235-245.
31. Sapra, P.; Allen, T. M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res., 2002, 62(24), 7190-7194.
32. Maruyama, K.; Ishida, O.; Takizawa, T.; Moribe, K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev., 1999, 40(1-2), 89-102.
33. Zhou, Y.; Drummond, D. C.; Zou, H.; Hayes, M. E.; Adams, G. P.; Kirpotin, D. B.; Marks, J. D. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol., 2007, 371(4), 934-947.
34. Drummond, D. C.; Hong, K.; Park, J. W.; Benz, C. C.; Kirpotin, D. B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm., 2000, 60, 285-332.
35. Stella, B.; Arpicco, S.; Peracchia, M. T.; Desmaele, D.; Hoebeke, J.; Renoir, M.; D'Angelo, J.; Cattel, L.; Couvreur, P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci., 2000, 89(11), 1452-1464.
36. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103(16), 6315-6320.
37. Karmali, P. P.; Kotamraju, V. R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell, M.; Ruoslahti, E. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine, 2009, 5(1), 73-82.
38. Laakkonen, P.; Porkka, K.; Hoffman, J. A.; Ruoslahti, E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med., 2002, 8(7), 751-755.
39. Montet, X.; Funovics, M.; Montet-Abou, K.; Weissleder, R.; Josephson, L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem., 2006, 49(20), 6087-6093.
40. Kraus, M.; Wolf, B. Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: a computer analysis. Tumour Biol., 1996, 17(3), 133-154.
41. Modi, S.; Swetha, M. G.; Goswami, D.; Gupta, G. D.; Mayor, S.; Krishnan, Y. A DNA nanomachine that maps spatial and temporal pH changes inside living cells. Nat. Nanotechnol., 2009, 4, 325-330.
42. Fattal, E.; Couvreur, P.; Dubernet, C., "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv. Drug Deliv. Rev., 2004, 56(7), 931-946.
43. Roux, E.; Francis, M.; Winnik, F. M.; Leroux, J. C. Polymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugs. Int. J. Pharm. 2002, 242(1-2), 25-36.
44. Simoes, S.; Moreira, J. N.; Fonseca, C.; Duzgunes, N.; de Lima, M. C. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev., 2004, 56(7), 947-965.
45. Lee, E. S.; Gao, Z.; Bae, Y. H., Recent progress in tumor pH targeting nanotechnology. J. Control. Release, 2008, 132(3), 164-170.
46. Kim, D.; Lee, E. S.; Oh, K. T.; Gao, Z. G.; Bae, Y. H., Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small, 2008, 4(11), 2043-2050.
47. Lee, E. S.; Kim, D.; Youn, Y. S.; Oh, K. T.; Bae, Y. H. A virus-mimetic nanogel vehicle. Angew. Chem. Int. Ed., 2008, 47(13), 2418-2421.
48. Griset, A. P.; Walpole, J.; Liu, R.; Gaffey, A.; Colson, Y. L.; Grinstaff, M. W., Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc., 2009, 131(7), 2469-2471.
49. Koval, M.; Preiter, K.; Adles, C.; Stahl, P. D.; Steinberg, T. H. Size of IgG-opsonized particles determines macrophage response during internalization. Exp. Cell Res., 1998, 242(1), 265-273.
50. Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D., Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J., 2004, 377(Pt 1), 159-169.
51. Huwyler, J.; Cerletti, A.; Fricker, G.; Eberle, A. N.; Drewe, J., Bypassing of P-glycoprotein using immunoliposomes. J. Drug Target, 2002, 10(1), 73-79.
52. Rapoport, N.; Marin, A.; Luo, Y.; Prestwich, G. D.; Muniruzzaman, M. D., Intracellular uptake and trafficking of Pluronic micelles in drug-sensitive and MDR cells: effect on the intracellular drug localization. J. Pharm. Sci., 2002, 91(1), 157-170.
53. Sahoo, S. K.; Labhasetwar, V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm., 2005, 2(5), 373-383.
54. Thierry, A. R.; Vige, D.; Coughlin, S. S.; Belli, J. A.; Dritschilo, A.; Rahman, A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J., 1993, 7(6), 572-579.
55. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 1987, 84(21), 7735-7738.
56. Patel, N. M.; Nozaki, S.; Shortle, N. H.; Bhat-Nakshatri, P.; Newton, T. R.; Rice, S.; Gelfanov, V.; Boswell, S. H.; Goulet, R. J., Jr.; Sledge, G. W., Jr.; Nakshatri, H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene, 2000, 19(36), 4159-4169.
57. van Vlerken, L. E.; Duan, Z.; Seiden, M. V.; Amiji, M. M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res., 2007, 67(10), 4843-4850.
58. Zhang, L.; Radovic-Moreno, A. F.; Alexis, F.; Gu, F. X.; Basto, P. A.; Bagalkot, V.; Jon, S.; Langer, R. S.; Farokhzad, O. C. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem., 2007, 2(9), 1268-1271.